CyFlow CD97 FITC
| 品番 | AU837788 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD97 FITC,MEM-180 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 2 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 FITC (CD051682) |
||
| 反応性|交差吸着 | Human | レーザー | Blue |
| 抗原 | CD97, EMR1 | 最大蛍光波長 | 518 nm |
| クローン | MEM-180 | 最大励起波長 | 490 to 495 nm |
| ホスト | Mouse | 標識/Format | FITC |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD97 FITC,MEM-180
特異性
The mouse monoclonal antibody MEM-180 recognizes an unique epitope on CD97 antigen, a 75-85 kDa surface glycoprotein of G-protein-coupled receptor family, expressed on activated B and T lymphocytes, monocytes/macrophages, dendritic cells and granulocytes.
抗原情報
CD97 is a G-protein-coupled seven-span transmembrane adhesive receptor that is constitutively expressed on granulocytes and monocytes and rapidly upregulated on T and B cells upon activation. CD97 is produced in alternatively spliced forms and its cellular ligand is CD55 (DAF), which protects various cell types from complement-mediated damage. Interaction of CD97 on leukocytes and CD55 on vessel cells probably facilitate leukocyte activation and migration into the tissues, similarly, CD97 seems to play a role in tumor migration and invasiveness. CD97 is involved in T cell regulation and peripheral granulocyte homeostasis.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co‑regulatory protein complex, CD97‑CD55. J·Biol·Chem. 2007·Jul·27; 282(30):22023‑32. <·PMID:·17449467·>
• Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, Aust G: Individual cell‑based models of tumor‑environment interactions: Multiple effects of CD97 on tumor invasion. Am·J·Pathol. 2006·Nov; 169(5):1802‑11. <·PMID:·17071601·>
• Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, Laman JD, Hintzen RQ: Expression of the EGF‑TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J·Neuroimmunol. 2002·Nov; 132(1‑2):156‑63. <·PMID:·12417446·>
• Wang T, Tian L, Haino M, Gao JL, Lake R, Ward Y, Wang H, Siebenlist U, Murphy PM, Kelly K: Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect·Immun. 2007·Mar; 75(3):1144‑53. <·PMID:·17158902·>
• Wobus M, Vogel B, Schmücking E, Hamann J, Aust G: N‑glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int·J·Cancer. 2004·Dec·10; 112(5):815‑22. <·PMID:·15386373·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN